Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer

Article metrics


cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects. However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7


  1. 1

    Prestayko AW, D'Aoust JC, Issell BF, Crooke ST . Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev 1979; 6: 17–39.

  2. 2

    Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522–1534.

  3. 3

    Galanski M . Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov 2006; 1: 285–295.

  4. 4

    Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK et al. beta-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res 2013; 33: 1421–1428.

  5. 5

    Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145–1153.

  6. 6

    Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573–584.

  7. 7

    Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869–1883.

  8. 8

    Koberle B, Tomicic MT, Usanova S, Kaina B . Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010; 1806: 172–182.

  9. 9

    Winter C, Albers P . Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2011; 7: 43–53.

  10. 10

    Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ . Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672–684.

  11. 11

    Kelman AD, Peresie HJ . Mode of DNA binding of cis-platinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed. Cancer Treat Rep 1979; 63: 1445–1452.

  12. 12

    Sanderson BJ, Ferguson LR, Denny WA . Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res. 1996; 355: 59–70.

  13. 13

    Siddik ZH . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265–7279.

  14. 14

    Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2: 257–269.

  15. 15

    Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39: 74–88.

  16. 16

    Finn OJ . Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23: viii6–viii9.

  17. 17

    McDonnell AM, Nowak AK, Lake RA . Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol 2011; 33: 353–367.

  18. 18

    Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F . Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579–1587.

  19. 19

    Finn OJ . Cancer immunology. New Engl J Med 2008; 358: 2704–2715.

  20. 20

    Coussens LM, Zitvogel L, Palucka AK . Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286–291.

  21. 21

    Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691–1701.

  22. 22

    Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54–61.

  23. 23

    Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050–1059.

  24. 24

    Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337: 1678–1684.

  25. 25

    Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metast Rev 2011; 30: 61–69.

  26. 26

    Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63ra94.

  27. 27

    Chao MP, Majeti R, Weissman IL . Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 2012; 12: 58–67.

  28. 28

    Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482–491.

  29. 29

    Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147–1158.

  30. 30

    Mayo JG . Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 2 1972; 3: 325–330.

  31. 31

    Talmadge JE, Singh RK, Fidler IJ, Raz A . Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007; 170: 793–804.

  32. 32

    Kelland LR . Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004; 40: 827–836.

  33. 33

    Phernambucq EC, Biesma B, Smit EF, Paul MA, vd Tol A, Schramel FM et al. Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). Br J Cancer 2006; 95: 470–474.

  34. 34

    Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ et al. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma–a randomized phase II trial. Lung Cancer 2008; 62: 334–343.

  35. 35

    Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, et al. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 2466–2473.

  36. 36

    Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A et al. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer 2013; 108: 265–270.

  37. 37

    Zitvogel L, Kepp O, Kroemer G . Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151–160.

  38. 38

    Galluzzi L, Senovilla L, Zitvogel L, Kroemer G . The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215–233.

  39. 39

    Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971–976.

  40. 40

    Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009; 28: 578–590.

  41. 41

    Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P et al. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle 2013; 12: 417–421.

  42. 42

    Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G . Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100–3104.

  43. 43

    Kim D, Hung CF, Wu TC . Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 2007; 18: 575–588.

  44. 44

    Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G . Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002; 265: 39–47.

  45. 45

    Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723–3728.

  46. 46

    Mordant P, Loriot Y, Lahon B, Castier Y, Leseche G, Soria JC et al. Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS ONE 2011; 6: e26073.

Download references


We are indepted to Dr Gonin (Gustave Roussy) for help in mouse experiments. CP is supported by the Deutsche Forschungsgemeinschaft (DFG) PF809/1-1. LS is supported by the Fondation Tourre, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and the SIRIC Cancer Research and Personalized Medicine (CARPEM). GK is supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).

Author information

Correspondence to G Kroemer or L Senovilla.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading